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Abstract
There are no studies to guide the optimal duration of therapy in severe community-acquired pneumonia (CAP). The aim of this study
was to determine whether 7 days of antibiotic treatment is equivalent to longer-course therapy in severe CAP. In this prospective
observational study, we included patients with severe CAP (CURB65 score 3–5) admitted to the hospital with signs and symptoms con-
sistent with pneumonia. A propensity score, derived through multiple logistic regression, was used to match patients into two groups:
treated for 7 days vs. treated for >7 days. Patients who died, were admitted to the intensive-care unit, developed complicated pneumo-
nia, failed to reach clinical stability or had positive cultures for microorganisms requiring prolonged treatment within the ﬁrst 7 days
were excluded. Patients outside the mutual range of the propensity score were also excluded. The primary outcome of this study was
30-day mortality. Secondary outcomes were subsequent requirement for mechanical ventilation and/or inotropic support and the devel-
opment of complicated pneumonia or re-admission within 30 days. Four hundred and twelve patients were suitable for derivation of
the propensity score. After matching on propensity score, 164 patients treated for 7 days were compared with 164 treated for >7 days;
they were well matched in terms of age, gender, comorbidities, and physiological parameters. The results showed no signiﬁcant differ-
ences in the primary and the secondary outcomes between the two groups. This study therefore suggests that, in the majority of
severe CAP patients who have clinically responded, antibiotics can be safely discontinued at 7 days.
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Introduction
Community-acquired pneumonia (CAP) is the commonest
infectious disease requiring hospitalization in western countries
[1–3]. Consequently, it is among the leading indications for
antibiotic therapy in primary and secondary care in the UK.
There has been an international move towards simplifying
and reducing antibiotic prescribing, owing to the increasing
incidence of hospital-acquired infections and antimicrobial
resistance. A recent international audit found that prolonged
courses of antibiotics for CAP are common, and that the
duration of antibiotic use often had little relationship with
patients’ response to treatment or initial severity [4].
Shortening the duration of antibiotic therapy therefore
offers a potential way to reduce antimicrobial use without
compromising patient safety. Randomized controlled trials
have demonstrated the efﬁcacy of short-course antibiotic
regimens in mild–moderate CAP [5,6], but no trial exists for
the severe group.
The British Thoracic Society recommend 7–10 days of
antibiotics for patients with severe CAP (CURB65 score 3–
5) in the 2009 guideline update, but this is based on expert
opinion only (grade D evidence) [7]. It is generally accepted
that patients admitted to the intensive-care unit (ICU), those
failing to respond to treatment within 7 days, those with
speciﬁc organisms such as Legionella pneumophila or Staphylo-
coccus aureus in blood cultures and those who develop com-
plications such as empyema require prolonged therapy [8].
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This leaves, however, a large proportion of severe CAP
patients for whom we hypothesize that shorter-course ther-
apy may be safe. The aim of this study was to determine
whether 7 days of antibiotic treatment is equivalent to
longer-course therapy in severe CAP patients admitted to
hospital.
Materials and Methods
In a prospective observational study [9], patients with CAP
and CURB65 score 3–5 were eligible for inclusion (2005–
2009) in NHS Lothian Hospitals, Edinburgh, UK. Patients
were included in the study if they presented with symptoms
and signs consistent with an acute lower respiratory tract
infection associated with new chest X-ray shadowing for
which there was no other explanation. The study excluded
patients with: hospital-acquired pneumonia (development of
symptoms >48 h following admission, or discharge from an
acute-care facility <2 weeks prior to admission); active malig-
nancy; immunosuppression (including human immunodeﬁ-
ciency virus infection, and use of long-term oral steroids or
other forms of immunosuppresant therapy); pneumonia
occurring as a terminal event in a palliative-care facility; and
pulmonary tuberculosis. The CURB65 score was calculated
as per guidelines [10].
Derivation and use of the propensity score
This was an observational study, and the duration of antibiotic
therapy was at the discretion of the attending physician. To
perform a propensity analysis, the probability that a patient
would receive treatment for 7 days vs. longer courses was
assessed with multivariable analysis. Only processes of care
and information available to clinicians at day 7 were included
in this analysis. The variables included in the multivariable
analysis included those considered by the authors to be plau-
sible as factors inﬂuencing a decision to give prolonged treat-
ment, and included clinical and laboratory tests, time to
clinical stability, and site of care, plus care by a respiratory vs.
non-respiratory physician. The multivariable model was used
to create a propensity score for each patient, representing
the probability that an individual patient would be treated for
7 days vs. longer-course therapy. Each patient treated with
7 days of therapy was then matched to a patient treated for
>7 days with a similar propensity score (within one decimal
place). This created two cohorts that were well matched for
measured confounders. Patients outside the mutual range of
the propensity score were excluded.
In practice, there are groups of patients who, in most
cases, are treated with prolonged (>7 days) antibiotic ther-
apy. We therefore excluded these groups, which included
patients who were admitted to the ICU on admission or
within 7 days, who failed to reach clinical stability within
7 days, who had positive microbiology test results indicating
infection with L. pneumophila, Gram-negative Enterobacteria-
cae, or Pseudomonas aeruginosa, who had blood culture posi-
tive for S. aureus, or who developed complicated pneumonia
(complicated parapneumonic effusion, empyema, or lung
abscess) within 7 days. Patients who died within 7 days were
also excluded.
Clinical stability was deﬁned as having all of the following
parameters, modiﬁed from Halm et al. [11], unless they rep-
resented the usual baseline status for that patient: tempera-
ture £37.2C; heart rate £100/min; respiratory rate £24/min;
systolic blood pressure ‡90 mmHg; oxygen saturation ‡90%
on room air; could maintain oral intake; and had normal
mental status at day 7.
Outcomes
The primary outcome of the study was 30-day mortality. As
a part of this study, we also looked at the need for mechani-
cal ventilation and/or inotropic support (MV/IS) after day 7,
the development of complicated pneumonia after day 7 and
re-admission within 30 days as the secondary outcomes.
Statistical analysis
Power calculation. In this equivalence study, with a one-
sided, 5% level of signiﬁcance, 90% power, 90% clinical suc-
cess and an equivalence of up to 10%, we would need 155
patients per group.
Analysis. All data were analysed with SPSS V.13 for win-
dows (SPSS, Chicago, IL, USA). The methods used to derive
the propensity score are described above. The propensity
score was used in two ways to correct for baseline dispari-
ties between groups. First, we compared the baseline charac-
teristics (age and comorbidities) and outcomes between the
matched patient groups (univariate analysis). Proportions
were compared by use of a chi-squared test, and continuous
variables were compared by use of a Mann–Whitney U-test.
Second, we conducted a multivariable analysis, including the
propensity score and duration of antibiotic therapy as inde-
pendent variables.
For univariate analysis, continuous variables were reported
as mean (± standard deviation) or median (interquartile
range) as appropriate. To explore possible confounding in
the analysis, sensitivity analyses were conducted, including all
412 patients suitable for matching rather than only those
matched according to propensity score. Second, to account
for the possibility of immortal time bias, we performed an
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analysis excluding all deaths on treatment in the >7-day
group. Finally, a multivariable logistic regression model was
constructed, incorporating 7 vs. >7 days and including all
potential predictors of mortality with a p-value <0.1 on uni-
variate analysis. As the study was already restricted to
CURB65 group 3–5, the CURB65 variables were not
included in this analysis. A p-value <0.05 was considered to
be statistically signiﬁcant for all analyses.
Results
Five hundred and seventy-four patients were admitted to
hospital with severe CAP during the study period. The mor-
tality rate for this group was 20.0%, and 19.2% required MV/
IS. Complicated pneumonia developed in 7.0%.
After exclusion of patients who died within 7 days, were
admitted to the ICU within 7 days, developed complicated
pneumonia within 7 days, failed to reach clinical stability
within 7 days, or had a microbiological diagnosis requiring
prolonged treatment (all deﬁned as circumstances in which a
decision to discontinue antibiotics at 7 days would be inap-
propriate), there were 412 patients suitable for derivation of
the propensity score (Fig. 1).
The 12 microbiological diagnoses leading to prolonged
treatment were Gram-negative Enterobacteriaceae (three
patients), P. aeruginosa (two patients), L. pneumophila (three
patients) and S. aureus bacteraemia (four patients).
Among the 412 patients suitable for matching, the mortal-
ity rate was lower, at 4.9%, the requirement for MV/IS was
4.1%, and 3.6% developed complicated pneumonia.
The propensity score was developed with 15 variables.
Table 1 shows the result of the logistic regression model.
With this model, 164 patients in whom antibiotics were dis-
continued at 7 days could be matched to 164 patients trea-
ted for >7 days (mean 12 days; standard deviation, 2.27 days;
range 8–28 days). In this group, the mortality rate was 3.7%,
and the subsequent requirement for MV/IS was 3.4%. Com-
plicated pneumonia developed in 2.4%.
Of the candidate variables for derivation of the propen-
sity score, younger age, earlier time to clinical stability and
a lower admission CURB65 score were associated with
shorter antibiotic courses. Multilobar shadowing was inde-
pendently associated with longer antibiotic courses
(Table 1).
FIG. 1. Flow of patients through the study.
ICU, intensive-care unit.




error) p-value OR (95% CI)
Age )0.02 (0.008) 0.04 0.98 (0.97–0.99)
Gender 0.05 (0.22) 0.8 1.05 (0.69–1.61)
Congestive cardiac failure 0.15 (0.27) 0.6 1.17 (0.69–1.98)
Liver disease )0.34 (0.52) 0.5 0.71 (0.26–1.97)
COPD 0.33 (0.24) 0.2 1.40 (0.87–2.24)
Diabetes )0.15 (0.32) 0.6 0.86 (0.46–1.60)
Smoking status 0.06 (0.24) 0.8 1.06 (0.67–1.70)
Antibiotic treatment prior
to hospital admission
0.24 (0.37) 0.5 1.27 (0.61–2.64)
Time to clinical stability 0.22 (0.05) <0.0001 1.24 (1.13–1.37)
Admission CURB65 score 0.80 (0.39) 0.04 2.22 (1.03–4.79)
Admission temperature )0.08 (0.12) 0.5 0.92 (0.83–1.16)
Multilobar shadowing 0.77 (0.33) 0.02 2.15 (1.14–4.08)
Positive microbiology test results 0.32 (0.28) 0.2 1.38 (0.80–2.38)
Hospital 1 vs. 2 0.01 (0.21) 0.9 1.01 (0.66–1.54)
Respiratory vs. general
medicine care
0.17 (0.29) 0.5 1.19 (0.67–2.10)
COPD, chronic obstructive pulmonary disease.
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Following propensity score matching, both groups were
well matched, as shown in Table 2. Also, there were no dif-
ferences between the two groups in terms of antibiotic
therapy on admission. Seventy-two per cent of patients
received guideline-compliant treatment in the 7-day group, as
compared with 74.4% 14-day group (p 0.6).
Outcomes between the two matched groups were com-
pared in terms of 30-day mortality (7 vs. >7 days (3% vs.
4.4%, p 0.8)), requirement for MV/IS (3.2% vs. 3.8%, p 0.5),
development of complicated pneumonia (3.1% vs. 1.9%,
p 0.7), and re-admission following hospital discharge (6.7%
vs. 5.5%, p 0.6).
Length of stay and re-admissions
Patients treated for 7 days had a signiﬁcantly shorter length
of hospital stay (median 6 days, interquartile range (IQR)
3–10 vs. 8 days, IQR 4–14, p 0.006). Re-admission following
hospital discharge was not signiﬁcantly higher in the 7-day
group than in the >7-day group (11 vs. nine patients (6.7%
vs. 5.5%)). Six re-admissions were directly CAP-related
(three in each group), whereas the remaining re-admissions
were related to comorbid conditions.
Multivariable analysis
In the multivariable analysis, incorporating the propensity
score as a covariate, 7-day antibiotic courses were not asso-
ciated with increased 30-day mortality (adjusted OR
(AOR) 0.67, 95% CI 0.21–2.16, p 0.5), MV/IS (AOR 0.92,
95% CI 0.27–3.16, p 0.9), or complicated pneumonia
(AOR 0.63, 95% CI 0.23–1.71, p 0.4). Therefore, none of
these ORs suggest a harmful effect of 7-day antibiotic
TABLE 2. Patient characteristics
7 days >7 days Excluded p-valuea
N 164 164 84
Clinical variables
Age ‡65 years, n (%) 120 (73.2) 124 (75.6) 66 (78.6) 0.8
Admission temperature (C) 37.7 (37.2–38.2) 37.4 (37.1–38.2) 38.0 (37.4–38.7) 0.7
Admission pulse rate/min 100 (90–118) 100 (90–115) 117 (100–125) 0.9
Admission hypoxaemia (PaO2 <8 kPa on air) (%) 61.6 58.5 63.1 0.7
Multilobar X-ray changes, n (%) 17 (10.4) 28 (17.1) 20 (23.8) 0.1
Time to clinical stability (days) 4 (3–5) 4 (3–5) 4 (3–6) 0.2
Admission C-reactive protein (mg/L) 176 (84–299) 169 (76–279) 290 (111–364) 0.7
C-reactive protein £50% of admission by day 7 (%) 92.1 89.6 83.3 0.6
CURB65: 3 (%) 66.5 56.1 60.7 0.07
CURB65: 4 (%) 29.9 35.4 31.0 0.3
CURB65: 5 (%) 3.6 8.5 8.3 0.1
Laboratory tests
Admission arterial pH 7.42 (7.35–7.48) 7.42 (7.37–7.46) 7.43 (7.36–7.48) 0.08
Admission sodium (mmol/L) 137 (135–139) 137 (134–139) 136 (133–138) 0.5
Admission glucose (mmol/L) 6.6 (5.9–8) 6.7 (5.6–8.2) 6.3 (5.2–7.5) 0.9
Admission white cell count (·109/L) 14.5 (11–17.8) 14.5 (10.8–19.1) 15.7 (11.8–21.0) 0.8
Admission albumin (g/L) 37 (32–40) 37 (34–39) 34 (32–37) 0.6
Comorbidities, n (%)
Diabetes mellitus 5 (3) 6 (3.7) 12 (14.3) 0.8
Current smoker 52 (31.7) 65 (39.6) 31 (36.9) 0.2
Congestive cardiac failure 41 (25) 41 (25) 24 (28.6) 0.9
Stroke 22 (13.5) 20 (12.1) 14 (16.7) 0.8
Renal failure 18 (11.0) 12 (7.3) 9 (10.7) 0.3
Liver disease 8 (4.9) 9 (5.5) 2 (2.4) 1.00
COPD 46 (28.0) 54 (32.9) 22 (26.2) 0.4
COPD, chronic obstructive pulmonary disease.
ap-value refers to the comparison between the 7-day group and >7-day group
TABLE 3. Results of the multivariable analysis
Covariate 30-day mortality MV/IS Complicated pneumonia
Main analysis
7 days vs. >7 days 0.67 (0.21–2.16), p 0.5 0.92 (0.27–3.16), p 0.9 0.63 (0.23–1.71), p 0.4
Excluding deaths on treatment
7 days vs. >7 days 0.95 (0.27–3.35), p 0.9 0.92 (0.27–3.14), p 0.9 0.63 (0.23–1.70), p 0.4
Including all patients suitable for matching (N = 412)
7 days vs. >7 days 1.20 (0.48–3.02), p 0.7 1.10 (0.57–2.13), p 0.8 0.65 (0.28–1.50), p 0.3
MV/IS, mechanical ventilation and/or inotropic support.
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courses on clinical outcomes. The results are shown in
Table 3.
Sensitivity analysis
Table 3 summarizes the results of the main multivariable
analyses and sensitivity analyses. To exclude the possibility of
immortal time bias, an analysis was performed excluding
deaths on treatment in the >7-day group. An additional sub-
analysis was performed with the inclusion of all patients suit-
able for matching (N = 412) rather than only those who
could be matched. Each of these subanalyses conﬁrmed the
ﬁndings of the main analysis (Table 3).
Finally, in a typical multivariable logistic regression analysis
(not utilizing the propensity score approach), incorporating
all 412 eligible patients, similar results were found as with
the propensity score approach. Seven-day treatments were
not signiﬁcantly associated with increased 30-day mortality
(AOR 0.71 (0.25–1.98)). The results of this analysis are
shown in Table 4.
Discussion
This study demonstrated no signiﬁcant difference in 30-day
mortality, need for MV/IS or major complications between
patients with severe CAP treated with 7 days of antibiotics
(clinical response by day 7) and those treated with pro-
longed antibiotic courses. This study therefore suggests
that, in the majority of high-severity CAP patients who
have clinically responded, antibiotics can be safely discontin-
ued at 7 days.
CAP is a common and potentially fatal infection, with high
healthcare costs [12,13]. Guidelines regarding the appropri-
ate duration of antibiotics can help to facilitate the manage-
ment of severe CAP patients. Unfortunately, to date, there
is little evidence to guide the optimal duration of therapy for
patients with high-severity CAP. Evidence suggests there are
large variations in duration of treatment [4]. The usual treat-
ment recommendation of 7–10 days for uncomplicated pneu-
monia is based on grade D evidence [7].
Shortening the duration of antibiotic therapy has many
potential advantages, but must be shown to be safe in terms
of risk of mortality and major complications [6]. If a shorter
duration of therapy is proven to be equally effective, this will
be of major importance in decreasing the usage of antibiotics.
This is all the more relevant currently, with increasing rates of
antibiotic resistance and hospital-acquired infections, such as
those with Clostridium difﬁcile [14,15].
A meta-analysis identiﬁed 15 studies suggesting that
shorter duration of antibiotics may be equally effective in
treating CAP [6]. These studies, however, were all focused
on mild–moderate pneumonia [16], and no randomized con-
trolled trials have established the appropriate duration of
therapy in severe CAP. A randomized control trial compar-
ing 8 and 15 days of antibiotics in adult ventilator-associated
pneumonia patients was performed in France between 1999
and 2002 [17]. The results showed that, among patients who
had received appropriate initial empirical therapy, with the
possible exception of those developing non-fermenting
Gram-negative bacillus infections, comparable clinical effec-
tiveness against ventilator-associated pneumonia was
obtained with the 8-day and 15-day treatment regimens.
In our study, of the 574 patients who were admitted to
the hospital with severe CAP, 328 were well matched and
allocated to either the 7-day or the >7-day group. The
results of this study are extremely encouraging, as it identi-
ﬁes a group of patients with severe CAP (CURB65 score 3–
5) who responded to an initial few days of antibiotics, and in
whom antibiotics could therefore be discontinued safely at
day 7.
In this study, we used Halm’s criteria to monitor response
to treatment [11]. Halm’s criteria have been widely validated,
and patients meeting these criteria have a low risk of compli-
cations [18,19]. Recent data suggest that, in lower respira-
tory tract infections, new biomarkers, such as procalcitonin,
can be used to monitor response to treatment and allow
early discontinuation of antibiotics [20–22]. In the recent
Pro-hosp study on the use of procalcitonin to reduce antibi-
otic duration, the average length of antibiotic treatment for
CAP was 10 days, and this was reduced to 7 days with
TABLE 4. Univariate and multivariable analysis not including the propensity score
Risk factor Univariate OR Unadjusted p-value Adjusted OR Adjusted p-value
Congestive cardiac failure 2.17 (0.86–5.48) 0.09 2.64 (0.86–8.07) 0.09
Chronic renal failure 3.51 (1.20–10.2) 0.02 3.46 (0.87–13.7) 0.08
Pulse rate >125/min 5.12 (2.03–12.9) 0.0006 2.39 (0.80–7.18) 0.1
Time to clinical stability 1.28 (1.05–1.56) 0.01 1.07 (0.85–1.36) 0.5
Acidosis 4.56 (1.78–11.7) 0.002 1.93 (0.62–5.95) 0.3
Multilobar shadowing 9.39 (3.67–24.0) <0.0001 6.30 (2.12–18.7) 0.0009
Albumin 3.66 (1.43–9.39) 0.007 3.58 (1.23–10.5) 0.02
7 days vs. >7 days 0.81 (0.32–2.02) 0.7 0.71 (0.25–1.98) 0.5
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procalcitonin guidance [22]. Procalcitonin and other new bio-
markers are not yet widely available. C-reactive protein is
more widely available, and can be used to monitor response
to treatment [19,23]. Recent studies have suggested that a
combination of Halm’s criteria and C-reactive protein can be
useful for monitoring response to treatment [19].
Future randomized studies are needed, using clinical crite-
ria or a combination of clinical criteria and biomarkers to
identify populations of patients in whom antibiotic use can
be reduced safely.
Our data suggest that, with the use of simple clinical crite-
ria, a population of CAP patients with a low risk of complica-
tions can be identiﬁed in whom antibiotics can be stopped
safely at 7 days.
This study excluded patients with certain microbiological
diagnoses that typically require prolonged antibiotic therapy,
and also excluded patients not responding to treatment,
according to clinical stability criteria, within 7 days. This there-
fore represents a population of patients who have received
antibiotic therapy appropriate for the causative pathogen and
who have clinically responded. Patients receiving inadequate
antibiotic therapy or failing to achieve clinical stability are at
increased risk of complications, and short-course antibiotic
therapy is likely to be inappropriate in this group.
Limitations of the study
The propensity score approach used in this study has limita-
tions. Many unmeasured confounders may have inﬂuenced
the decision to treat patients for >7 days rather than for
7 days, and only randomized control trials can deﬁnitively
account for this confounding.
Another limitation of this study is the sample size.
Although the outcomes were comparable between the treat-
ment groups in our study, the sample size was moderate and
only had an equivalence of up to 10%. Further randomized
control trials will also help to conﬁrm the non-inferiority of
a shorter duration of treatment in adults with severe CAP.
We also excluded patients with severe CAP, who either did
not respond clinically or developed complications within
7 days. Further studies to identify the optimal groups of
patients for short-course antibiotic treatment are needed.
Conclusion
Our study showed no signiﬁcant differences between two
well-matched groups of severe CAP patients treated for
7 days vs. >7 days. Future randomized controlled trials are
needed to determine whether shorter course of antibiotic
treatment can be used in high-severity CAP patients.
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